Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | GLS | O94925 | 4/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846095 | 0.90 | DGAT1 (0.42) | KMT2AMEN1GLSDGAT1TSHR | |
| SCHEMBL24846064 | 0.90 | KMT2A (0.47) | KMT2AMEN1GLSDGAT1RAB9A | |
| SCHEMBL24846115 | 0.89 | GLS (0.49) | KMT2AMEN1GLSRAB9ATSHR | |
| SCHEMBL24846054 | 0.87 | KMT2A (0.43) | KMT2AMEN1TSHRCYP1A2CYP3A4 | |
| SCHEMBL24846119 | 0.86 | KMT2A (0.39) | KMT2AMEN1GLSDGAT1RAB9A | |
| SCHEMBL24846603 | 0.85 | SMN1; SMN2 (0.39) | KMT2AMEN1DGAT1RAB9ATSHR | |
| SCHEMBL24846717 | 0.85 | CFTR (0.45) | KMT2AMEN1GLSRAB9ANPC1 | |
| SCHEMBL24846592 | 0.84 | KMT2A (0.45) | KMT2AMEN1GLSRAB9ANPC1 | |
| SCHEMBL24846086 | 0.84 | KMT2A (0.48) | KMT2AMEN1GLSDGAT1RAB9A | |
| SCHEMBL24954265 | 0.83 | MAPT (0.51) | KMT2AMEN1RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | KMT2A 3840/4885MEN1 3172/4885GLS 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.